Multiple Myeloma

Why trials studying Multiple Myeloma stopped, in this sample of ClinicalTrials.gov.

62 stopped trials with a clear reason; 85% ended for non-scientific reasons.

Reason	Trials	Share
slow accrual	25	40%
funding business	17	27%
safety	6	10%
logistics pi	5	8%
regulatory	3	5%
manufacturing supply	3	5%
other	2	3%
futility	1	2%

Trials

Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells
NCT07071909 · WITHDRAWN · funding business
“Funding unavailable”
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
NCT05971056 · TERMINATED · funding business
“Insufficient funding”
Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma
NCT05013437 · WITHDRAWN · logistics pi
“The original principal Investigator left the institution.”
Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma
NCT05908396 · TERMINATED · funding business
“Company Decision”
Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma
NCT04864522 · WITHDRAWN · slow accrual
“Slow accrual due to a crowded field of effective drugs by the time the study opened”
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
NCT05655546 · TERMINATED · regulatory
“On May 13, 2024, the FDA released a communication that Cue Health tests should no longer be used.”
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT05027594 · TERMINATED · funding business
“The decision is not based on emerging safety or efficacy concerns but on strategic reasons related to the changing and competitive treatment options in Multiple Myeloma”
Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
NCT05191472 · TERMINATED · slow accrual
“Slow Accrual”
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
NCT04912427 · TERMINATED · slow accrual
“Low accrual”
Study of Dara-Pembro for Multiple Myeloma Patients
NCT04361851 · WITHDRAWN · slow accrual
“Low enrollment due to competing studies”
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
NCT04398680 · WITHDRAWN · funding business
“Sponsor Decision”
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
NCT04827563 · TERMINATED · logistics pi
“Study terminated by PI”
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE
NCT04258683 · WITHDRAWN · slow accrual
“Study terminated due to changing treatment landscape”
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
NCT04730505 · TERMINATED · logistics pi
“Study faced multiple challenges and its launch was heavily impacted by COVID, which in turn has significantly impacted the deployment and adoption goals for a digital technology pilot. These factors led to the difficult decision to close the study.”
Physical Activity for Myeloma Autograft Longitudinal Study
NCT03946332 · TERMINATED · other
“The study has stopped after the investigator's decision. The latter desires to analyse the collected data at 60 patients.”
Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
NCT01125449 · WITHDRAWN · manufacturing supply
“Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche (Ireland).”
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
NCT04025216 · TERMINATED · safety
“The sponsor finds the risk/benefit analysis unfavorable and has terminated the study.”
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
NCT03657420 · WITHDRAWN · funding business
“Funding withdrawn by sponsor”
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
NCT03582033 · TERMINATED · funding business
“Study closed due to portfolio prioritization”
Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)
NCT03634800 · TERMINATED · slow accrual
“Lack of patient accruals.”
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
NCT03481556 · TERMINATED · regulatory
“The sponsor decided to terminate the study following an FDA request of a partial clinical hold.”
Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
NCT03266692 · TERMINATED · funding business
“Business reasons”
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
NCT03173092 · TERMINATED · other
“All participants on the study have concluded treatment, core study activities are complete, and the scientific goals of the study have been met.”
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT03215030 · TERMINATED · funding business
“Terminated by the sponsor for strategic reasons”
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
NCT03168100 · WITHDRAWN · slow accrual
“No study population. No subjects enrolled.”
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
NCT03288493 · TERMINATED · funding business
“Phase I portion of the study was completed. The phase II portion of the study was terminated early to focus on an Allogeneic BCMA CAR-T program.”
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
NCT02802163 · WITHDRAWN · manufacturing supply
“study drug unavailable”
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
NCT03117361 · TERMINATED · slow accrual
“PharmaMar has decided to end this study due to the slow recruitment rate of the trial”
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
NCT02928029 · TERMINATED · slow accrual
“Due to the changes of standard of care and the slow recruitment of participants.”
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
NCT03023527 · TERMINATED · safety
“Safety”
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
NCT02716805 · TERMINATED · regulatory
“FDA placed on partial hold due to additional data”
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
NCT02840110 · TERMINATED · funding business
“Business Decision”
BiRd vs. Rd as Initial Therapy in Multiple Myeloma
NCT02516696 · TERMINATED · slow accrual
“low enrollment”
A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib
NCT02115035 · WITHDRAWN · funding business
“Funding issues”
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
NCT02155634 · WITHDRAWN · slow accrual
“The study was terminated due to poor feasibility and lack of interest at the participating sites.”
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
NCT02110563 · TERMINATED · funding business
“Sponsor Decision”
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT
NCT03963024 · TERMINATED · slow accrual
“low rate of enrolment”
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
NCT02030483 · TERMINATED · funding business
“The company providing one of the study drugs withdrew its support due to low enrollment. Therefore, we had to close the study due to lack of funding.”
Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
NCT02773550 · TERMINATED · slow accrual
“Low recruiment.”
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
NCT02002598 · TERMINATED · slow accrual
“Slow accrual and loss of funding”
Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma
NCT01881789 · TERMINATED · safety
“A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ003 was halted during dose-escalation.”
CT Antigen TCR-Engineered T Cells for Myeloma
NCT01892293 · TERMINATED · funding business
“Sponsor Decision”
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
NCT01908387 · TERMINATED · slow accrual
“Due to Slow Accrual study was terminated.”
Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
NCT01965834 · TERMINATED · slow accrual
“Lack of adequate accrual.”
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
NCT01329289 · WITHDRAWN · logistics pi
“Clinical trial being transferred to Columbia University with the Investigator.”
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
NCT01416428 · TERMINATED · safety
“A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted.”
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT01055301 · WITHDRAWN · slow accrual
“lack of accrual”
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
NCT01470131 · TERMINATED · funding business
“Sponsor decision based on portfolio prioritization”
Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation
NCT01251952 · TERMINATED · manufacturing supply
“Drug unavailable”
Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma
NCT00843310 · TERMINATED · slow accrual
“Due to slow accrual”
Trial of Romidepsin and Bortezomib for Multiple Myeloma
NCT00765102 · TERMINATED · funding business
“There was a change in the Sponsor's research strategy; safety concerns were not a factor.”
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma
NCT00538824 · TERMINATED · slow accrual
“low enrollment”
In-Vivo Activated T-Cell Depletion to Prevent GVHD
NCT00594308 · TERMINATED · futility
“Treatment ineffective”
EMMA-1 (Erbitux for Multiple Myeloma)
NCT00368121 · TERMINATED · slow accrual
“Lack of recruitable patients”
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
NCT00366106 · TERMINATED · slow accrual
“Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed.”
Study of XL999 in Patients With Multiple Myeloma
NCT00304590 · TERMINATED · safety
“Study was terminated due to cardiac toxicities in the subjects”
Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
NCT02739594 · TERMINATED · slow accrual
“Slow recruitment”
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
NCT00240162 · TERMINATED · safety
“investigator letter from drug manufacturer stating animal studies showed increased risk of cancer which was an unknown adverse event”
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
NCT00361088 · TERMINATED · logistics pi
“Initial Principal Investigator left Moffitt”
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma
NCT00109889 · TERMINATED · slow accrual
“poor accrual”
UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
NCT00113919 · TERMINATED · slow accrual
“Due to poor accrual”
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
NCT00255684 · TERMINATED · slow accrual
“low accrual”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.